Xenon Pharmaceuticals
Stock Forecast, Prediction & Price Target
Xenon Pharmaceuticals (XENE) stock Price Target by analysts
$51.5
Potential upside: 37.84%
Xenon Pharmaceuticals price prediction
What is Xenon Pharmaceuticals stock analysts` prediction?
Xenon Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Xenon Pharmaceuticals in the last 3 months, the avarage price target is $51.5, with a high forecast of $NaN. The average price target represents a 37.84% change from the last price of $37.36.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Xenon Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Xenon Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Danielle Brill Raymond James | 0% 0/2 | 12 months ago | $50 33.83% upside | $39.42 | TheFly | Previous targets (1) |
Douglas Tsao H.C. Wainwright | 0% 0/1 | 12 months ago | $53 41.86% upside | $39.37 | TheFly | Previous targets (0) |
Laura Chico Wedbush | 0% 0/1 | about 1 year ago | $49 31.15% upside | $41.05 | TheFly | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/1 | over 1 year ago | $55 47.21% upside | $36.25 | StreetInsider | Previous targets (0) |
Unknown Goldman Sachs | N/A | almost 3 years ago | $60 60.59% upside | $39.57 | Benzinga | N/A |
Unknown Wells Fargo | N/A | almost 3 years ago | $50 33.83% upside | $35.86 | Benzinga | N/A |
Unknown Guggenheim | N/A | almost 3 years ago | $49 31.15% upside | $35 | Benzinga | N/A |
Danielle Brill Raymond James | 0% 0/2 | almost 3 years ago | $52 39.18% upside | $35.52 | TheFly | Previous targets (1) |
Unknown Leerink Partners | N/A | about 3 years ago | $46 23.12% upside | $39.68 | Benzinga | N/A |
Unknown RBC Capital | N/A | about 3 years ago | $46 23.12% upside | $40.53 | Benzinga | N/A |
Unknown Wedbush | N/A | over 3 years ago | $41 9.74% upside | $30.85 | Benzinga | N/A |
Unknown RBC Capital | N/A | over 3 years ago | $41 9.74% upside | $27.07 | Benzinga | N/A |
Xenon Pharmaceuticals Financial Estimates
Xenon Pharmaceuticals Revenue Estimates
Xenon Pharmaceuticals EBITDA Estimates
Xenon Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $18.43M N/A | $9.43M -48.83% | $0 -100% | Avg: $9.38M Low: $9.38M High: $9.38M avg. 0% | Avg: $60.58M Low: $60.58M High: $60.58M avg. 545.30% | Avg: $366.81M Low: $366.81M High: $366.81M avg. 505.45% | Avg: $646.66M Low: $646.66M High: $646.66M avg. 76.29% |
Net Income
% change YoY
| $-78.88M N/A | $-125.37M -58.93% | $-182.39M -45.48% | Avg: $-268.68M Low: $-282.94M High: $-68.22M avg. -47.31% | Avg: $-305.88M Low: $-311.70M High: $-107.69M avg. -13.84% | Avg: $-59.36M Low: $-59.36M High: $-59.36M avg. 80.59% | Avg: $96.06M Low: $96.06M High: $96.06M avg. 261.83% |
EBITDA
% change YoY
| $-78.99M N/A | $-129.14M -63.48% | $-210.51M -63.00% | Avg: $-5.58M Low: $-5.58M High: $-5.58M avg. 97.34% | Avg: $-36.02M Low: $-36.02M High: $-36.02M avg. -545.30% | Avg: $-218.11M Low: $-218.11M High: $-218.11M avg. -505.45% | Avg: $-384.52M Low: $-384.52M High: $-384.52M avg. -76.29% |
EPS
% change YoY
| -$1.81 N/A | -$2.07 -14.36% | -$2.73 -31.88% | Avg: -$3.2 Low: -$4.23 High: -$1.02 avg. -17.10% | Avg: -$3.39 Low: -$4.66 High: -$1.61 avg. -6.06% | Avg: -$0.89 Low: -$0.89 High: -$0.89 avg. 73.82% | Avg: $1.44 Low: $1.44 High: $1.44 avg. 261.83% |
Operating Expenses
% change YoY
| $97.43M N/A | $138.57M 42.23% | $46.54M -66.41% | Avg: $14.37M Low: $14.37M High: $14.37M avg. -69.12% | Avg: $92.73M Low: $92.73M High: $92.73M avg. 545.30% | Avg: $561.49M Low: $561.49M High: $561.49M avg. 505.45% | Avg: $989.87M Low: $989.87M High: $989.87M avg. 76.29% |
FAQ
What is Xenon Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 70.31% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -282.94M, average is -268.68M and high is -68.22M.
What is Xenon Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 281.76% in 2025-2028.
We have gathered data from 10 analysts. Their low revenue estimate is $9.38M, average is $9.38M and high is $9.38M.
What is Xenon Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 78.12% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$4.23, average is -$3.2 and high is $-1.02.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Xenon Pharmaceuticals stock. The most successful analyst is Danielle Brill.